Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Ultragenyx Pharmaceutical Inc’s stock clocked out at $36.91, up 0.82% from its previous closing price of $36.61. In other words, the price has increased by $0.82 from its previous closing price. On the day, 1.41 million shares were traded.
Ratios:
To gain a deeper understanding of RARE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 6.17 whereas as Long-Term Debt/Eq ratio is at 5.70.
On June 06, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $56 to $67. On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.RBC Capital Mkts initiated its Outperform rating on April 22, 2024, with a $77 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 05 ’25 when Crombez Eric sold 520 shares for $39.24 per share. The transaction valued at 20,405 led to the insider holds 71,530 shares of the business.
Crombez Eric sold 242 shares of RARE for $8,497 on Apr 21 ’25. The EVP and Chief Medical Officer now owns 71,680 shares after completing the transaction at $35.11 per share. On Mar 06 ’25, another insider, Horn Howard, who serves as the Chief Financial Officer of the company, sold 1,785 shares for $40.40 each. As a result, the insider received 72,114 and left with 106,169 shares of the company.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $29.59. The 50-Day Moving Average of the stock is 3.08%, while the 200-Day Moving Average is calculated to be -18.09%.
Shares Statistics:
A total of 93.74M shares are outstanding, with a floating share count of 88.37M. Insiders hold about 6.53% of the company’s shares, while institutions hold 95.27% stake in the company.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.01 and low estimates of -$1.51.
Analysts are recommending an EPS of between -$4.51 and -$5.78 for the fiscal current year, implying an average EPS of -$5.32. EPS for the following year is -$3.56, with 9.0 analysts recommending between -$1.83 and -$4.68.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $161.67M. It ranges from a high estimate of $174M to a low estimate of $148M. As of the current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $147.03MFor the next quarter, 15 analysts are estimating revenue of $164.17M. There is a high estimate of $174.43M for the next quarter, whereas the lowest estimate is $150M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $669.35M, while the lowest revenue estimate was $589M, resulting in an average revenue estimate of $649.82M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $835.73M in the next fiscal year. The high estimate is $1.02B and the low estimate is $698.47M.
